– NASDAQ:CAPR
Founder-led company
stock price today
$7.66
-6.42
-45.6%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
stock price monthly change
+220.00%
month
stock price quarterly change
+220.00%
quarter
stock price yearly change
+177.16%
year
key metrics
Market Cap | 590.65M |
Enterprise value | N/A |
P/E | -3.64 |
EV/Sales | -4.35 |
EV/EBITDA | 0.47 |
Price/Sales | 0.06 |
Price/Book | N/A |
PEG ratio | 0.10 |
EPS | -0.87 |
Revenue | 27.09M |
EBITDA | -25.68M |
Income | -24.31M |
Revenue Q/Q | 64.29% |
Revenue Y/Y | 389.52% |
Profit margin | -938.23% |
Oper. margin | -952.44% |
Gross margin | 0% |
EBIT margin | -952.44% |
EBITDA margin | -94.78% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freestock price history
stock forecast
financial statements
Average Price Target
$31.6
Potential upside: 312.53%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 3.91M | -7.36M | -188.04% |
|---|---|---|---|
| Sep 2023 | 6.18M | -6.39M | -103.31% |
| Dec 2023 | 12.08M | -762.08K | -6.3% |
| Mar 2024 | 4.90M | -9.79M | -199.6% |
| Jun 2023 | 46011198 | 43.28M | 94.06% |
|---|---|---|---|
| Sep 2023 | 37152330 | 38.93M | 104.81% |
| Dec 2023 | 58734327 | 36.13M | 61.52% |
| Mar 2024 | 49444442 | 31.00M | 62.72% |
| Jun 2023 | -9.41M | 6.46M | 2.18M |
|---|---|---|---|
| Sep 2023 | -8.79M | 7.72M | 221.08K |
| Dec 2023 | -11.59M | -5.86M | 23.16M |
| Mar 2024 | -1.26M | -9.50M | 2.29M |
alternative data
| Aug 2023 | 74 |
|---|---|
| Sep 2023 | 74 |
| Oct 2023 | 74 |
| Nov 2023 | 74 |
| Dec 2023 | 74 |
| Jan 2024 | 74 |
| Feb 2024 | 74 |
| Mar 2024 | 101 |
| Apr 2024 | 101 |
| May 2024 | 101 |
| Jun 2024 | 101 |
| Jul 2024 | 101 |
other data
3.06%
-8.14%
of CAPR is owned by hedge funds
19
-11
751.02K
-1.98M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Oct 2023 | 22993 | 0 |
| Sep 2024 | 2798507 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | KRASNEY KAREN officer: EVP, GEN.. | Common Stock | 8,000 | $1.39 | $11,120 | ||
Option | KRASNEY KAREN officer: EVP, GEN.. | Stock Option (Right to Buy) | 5,000 | $1.39 | $6,950 | ||
Option | LITVACK FRANK director | Common Stock | 20,391 | $1.1 | $22,430 | ||
Option | LITVACK FRANK director | Warrants (Right to Buy) | 20,391 | $1.1 | $22,430 | ||
Purchase | NIPPON SHINYAKU CO LTD 10 percent owner | Common Stock, par value $0.001 per share | 2,798,507 | $5.36 | $14,999,998 | ||
Option | MUSKET DAVID B director | Common Stock | 34,000 | $1.39 | $47,260 | ||
Option | MUSKET DAVID B director | Stock Option (Right to Buy) | 34,000 | $1.39 | $47,260 | ||
Option | COLLIER EARL M JR director | Common Stock | 30,000 | $1.39 | $41,700 | ||
Option | COLLIER EARL M JR director | Stock Option (Right to Buy) | 30,000 | $1.39 | $41,700 | ||
Option | MUSKET DAVID B director | Common Stock | 16,156 | $1.39 | $22,457 |
| Quarter | Transcript |
|---|---|
| Q1 2024 13 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 29 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 14 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 7 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Ms. Karen G. Krasney (1953) Executive Vice President, Gen. Counsel & Sec. | $346,750 |
Mr. Anthony J. Bergmann M.B.A. (1986) Chief Financial Officer & Corporation Treasurer | $316,500 |
Dr. Linda Marbán (1963) Co-Founder, Pres, Chief Executive Officer & Director | $196,500 |
Dr. Frank Isaac Litvack FACC, M.D. (1956) Executive Chairman | $120,000 |
Capricor: A Hold Rating With Regulatory FDA Form Given For Deramiocel Advancement
Capricor Therapeutics' Buy Thesis Ahead Of Deramiocel PDUFA Date
Capricor: High-Reward DMD Treatment Bet With Strong Data And Looming FDA Decision
I Missed The Quantum Rally - I Won't Miss The Next One
Capricor: Rolling BLA Submission Of CAP-1002 To Get DMD Treatment Program Going
Capricor Therapeutics, Sarepta Therapeutics: A Promising Clinical-Stage Biotech And A Commercial-Stage Leader In Duchenne Muscular Dystrophy
Capricor: Q4 2023 Interim Analysis For DMD Treatment Makes This A Must Watch
-
What's the price of stock today?
One share of stock can currently be purchased for approximately $7.66.
-
When is 's next earnings date?
Unfortunately, 's (CAPR) next earnings date is currently unknown.
-
Does pay dividends?
No, does not pay dividends.
-
How much money does make?
has a market capitalization of 590.65M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 887.79% to 25.18M US dollars.
-
What is 's stock symbol?
null is traded on the NASDAQ under the ticker symbol "CAPR".
-
What is 's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of ?
Shares of can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are 's key executives?
's management team includes the following people:
- Ms. Karen G. Krasney Executive Vice President, Gen. Counsel & Sec.(age: 72, pay: $346,750)
- Mr. Anthony J. Bergmann M.B.A. Chief Financial Officer & Corporation Treasurer(age: 39, pay: $316,500)
- Dr. Linda Marbán Co-Founder, Pres, Chief Executive Officer & Director(age: 62, pay: $196,500)
- Dr. Frank Isaac Litvack FACC, M.D. Executive Chairman(age: 69, pay: $120,000)
-
Is founder-led company?
Yes, is a company led by its founder Dr. Linda Marbán.
-
How many employees does have?
As Jul 2024, employs 101 workers.
-
When went public?
null is publicly traded company for more then 18 years since IPO on 13 Feb 2007.
-
What is 's official website?
The official website for is capricor.com.
-
Where are 's headquarters?
is headquartered at 10865 Road to the Cure, San Diego, CA.
-
How can i contact ?
's mailing address is 10865 Road to the Cure, San Diego, CA and company can be reached via phone at +31 3583200.
-
What is stock forecast & price target?
Based on 4 Wall Street analysts` predicted price targets for in the last 12 months, the avarage price target is $31.6. The average price target represents a 312.53% change from the last price of $7.66.
company profile:
Exchange:
NASDAQ
Full time employees:
101
Industry:
Biotechnology
Sector:
Healthcare
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.
10865 Road to the Cure
San Diego, CA 92121
San Diego, CA 92121
CIK: 0001133869
ISIN: US14070B3096
CUSIP: 14070B309
